Iconic Therapeutics: Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

(marketscreener.com) - Exelixis gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic -https://www.marketscreener.com/quote/stock/EXELIXIS-INC-9235/news/Exelixis-and-Iconic-Therapeutics-Amend-Option-and-License-Agreement-for-XB002-an-Antibody-Drug-Conj-37480165/?utm_medium=RSS&utm_content=20220106